TherapeuticsMD (TXMD) Misses Q3 EPS by $1.09

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($3.13), $1.09 worse than the analyst estimate of ($2.04). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $30.2 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Vireo Growth completes acquisition of C21 Investments
• BMO starts chip stocks coverage: Here are its preferred picks